Dr Reddy's Laboratories Net Acquisitions/Divestitures 2010-2024 | RDY
Dr Reddy's Laboratories annual/quarterly net acquisitions/divestitures history and growth rate from 2010 to 2024. Net acquisitions/divestitures can be defined as the total change in cash resulting from both investments in businesses and sales of businesses or business segments.
- Dr Reddy's Laboratories net acquisitions/divestitures for the quarter ending December 31, 2024 were $-0.601B, a 0% increase year-over-year.
- Dr Reddy's Laboratories net acquisitions/divestitures for the twelve months ending December 31, 2024 were $-1.215B, a 0% increase year-over-year.
- Dr Reddy's Laboratories annual net acquisitions/divestitures for 2024 were $0B, a 0% decline from 2023.
- Dr Reddy's Laboratories annual net acquisitions/divestitures for 2023 were $0B, a 100% decline from 2022.
- Dr Reddy's Laboratories annual net acquisitions/divestitures for 2022 were $-0.004B, a 98.11% decline from 2021.
Dr Reddy's Laboratories Annual Net Acquisitions/Divestitures
(Millions of US $) |
| 2024 |
$N/A |
| 2023 |
$N/A |
| 2022 |
$-4 |
| 2021 |
$-212 |
| 2020 |
$N/A |
| 2019 |
$N/A |
| 2018 |
$N/A |
| 2017 |
$N/A |
| 2016 |
$-120 |
| 2015 |
$-4 |
| 2014 |
$0 |
| 2013 |
$-32 |
| 2012 |
$0 |
| 2011 |
$-26 |
| 2010 |
$0 |
| 2009 |
$-63 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$11.261B |
$3.350B |
|
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|
